Erhan Keleş

449 total citations
10 papers, 359 citations indexed

About

Erhan Keleş is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erhan Keleş has authored 10 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Organic Chemistry and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erhan Keleş's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Click Chemistry and Applications (4 papers) and Advanced Breast Cancer Therapies (2 papers). Erhan Keleş is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Click Chemistry and Applications (4 papers) and Advanced Breast Cancer Therapies (2 papers). Erhan Keleş collaborates with scholars based in Switzerland, Canada and United States. Erhan Keleş's co-authors include Yang Song, Wen‐Ji Dong, Yuehe Lin, Dan Du, Chiara Borsari, Matthias P. Wymann, Paul Hebeisen, Rohitha Sriramaratnam, Florent Beaufils and Denise Rageot and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Clinical Cancer Research.

In The Last Decade

Erhan Keleş

10 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erhan Keleş Switzerland 7 232 77 65 52 41 10 359
Jason H. Williams United States 12 319 1.4× 53 0.7× 53 0.8× 68 1.3× 51 1.2× 27 532
M.W. Hayman United Kingdom 9 169 0.7× 68 0.9× 95 1.5× 35 0.7× 48 1.2× 15 441
Jian Jiang China 11 272 1.2× 47 0.6× 106 1.6× 83 1.6× 31 0.8× 24 472
Sonia Leclerc Canada 7 148 0.6× 45 0.6× 36 0.6× 44 0.8× 42 1.0× 8 276
Jessica Larsen United States 10 163 0.7× 76 1.0× 98 1.5× 159 3.1× 22 0.5× 25 388
Barbara Ziemba Poland 12 376 1.6× 76 1.0× 51 0.8× 91 1.8× 19 0.5× 24 519
Chi‐Hsien Wang Taiwan 12 175 0.8× 54 0.7× 29 0.4× 21 0.4× 31 0.8× 27 367
Shiva Akbari‐Birgani Iran 13 157 0.7× 34 0.4× 124 1.9× 67 1.3× 21 0.5× 29 408

Countries citing papers authored by Erhan Keleş

Since Specialization
Citations

This map shows the geographic impact of Erhan Keleş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erhan Keleş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erhan Keleş more than expected).

Fields of papers citing papers by Erhan Keleş

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erhan Keleş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erhan Keleş. The network helps show where Erhan Keleş may publish in the future.

Co-authorship network of co-authors of Erhan Keleş

This figure shows the co-authorship network connecting the top 25 collaborators of Erhan Keleş. A scholar is included among the top collaborators of Erhan Keleş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erhan Keleş. Erhan Keleş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Keleş, Erhan, Luka Raguž, Thorsten Schaefer, et al.. (2024). Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling. Chemical Science. 15(48). 20274–20291. 1 indexed citations
2.
Borsari, Chiara, Erhan Keleş, Jacob A. McPhail, et al.. (2022). Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα. Journal of the American Chemical Society. 144(14). 6326–6342. 40 indexed citations
3.
Borsari, Chiara, et al.. (2021). Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability. RSC Medicinal Chemistry. 12(4). 579–583. 8 indexed citations
4.
Keleş, Erhan, Chiara Borsari, Rohitha Sriramaratnam, Thorsten Schäfer, & Matthias P. Wymann. (2021). Abstract 1378: A novel, highly potent PI3Kα covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells. Cancer Research. 81(13_Supplement). 1378–1378. 1 indexed citations
5.
Borsari, Chiara, Erhan Keleş, Jacob A. McPhail, et al.. (2021). Abstract 291: Development of optimized chemical probes targeting PI3Ka to deconvolute the role of class I PI3Ks isoforms in insulin signaling. Cancer Research. 81(13_Supplement). 291–291. 1 indexed citations
7.
Rageot, Denise, Thomas Bohnacker, Erhan Keleş, et al.. (2019). (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry. 62(13). 6241–6261. 49 indexed citations
8.
Borsari, Chiara, Denise Rageot, Florent Beaufils, et al.. (2019). Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety. ACS Medicinal Chemistry Letters. 10(10). 1473–1479. 34 indexed citations
9.
Stuckey, Daniel W., Sara Pignatta, Clemens Reinshagen, et al.. (2017). Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas. Clinical Cancer Research. 23(22). 7047–7058. 43 indexed citations
10.
Keleş, Erhan, Yang Song, Dan Du, Wen‐Ji Dong, & Yuehe Lin. (2016). Recent progress in nanomaterials for gene delivery applications. Biomaterials Science. 4(9). 1291–1309. 164 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026